A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs.
Surgery, chemotherapy, and irradiation have been used singly or in combination to treat dogs with cutaneous grade-2 mast cell tumors (MCT). However, optimal treatment has not been established. At The Animal Medical Center, 32 dogs with grade 2, stage 0 MCT received cobalt radiation treatment to a dose of 54 Gy; 94% had a disease-free interval of 1 year. The 2-,3-,4-, and 5-year disease-free intervals were 86%. Survival rates were 100% for 1 year and 96% for 2 to 5 years, with only 1 death caused by MCT. Primary site was not a prognostic factor for survival in this study. Minimal toxicity was observed and was limited to acute cutaneous reactions. Late-term reactions to radiation therapy were mild and considered acceptable in all cases. No deaths occurred due to treatment, and no dog was eliminated from the study because of radiation therapy toxicity. Radiation therapy appears to be an effective treatment for dogs with grade 2, stage 0 MCT.
al-Sarraf
R
R
Donaldson-Arwood Cancer Clinic, Animal Medical Center, New York, NY, USA.
Mauldin
G N
GN
Patnaik
A K
AK
Meleo
K A
KA
D000818:Animals; D004283:Dog Diseases / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D004285:Dogs; D005260:Female; D008297:Male; D012515:Mast-Cell Sarcoma / Q000473:pathology / Q000532:radiotherapy / Q000662:veterinary*; D011379:Prognosis; D011446:Prospective Studies; D011878:Radiotherapy / Q000401:mortality / Q000592:standards / Q000662:veterinary*; D011879:Radiotherapy Dosage; D012878:Skin Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000662:veterinary*; D015996:Survival Rate